【摘要】 目的 探讨荷芪散加味结合非布司他治疗高尿酸血症伴胰岛素抵抗的临床效果。方法 选取2020年1月至2021年1月收治的80例高尿酸血症伴胰岛素抵抗患者为研究对象，按照随机数字表法将其分为对照组和观察组，各40例。对照组给予非布司他片治疗，研究组在对照组的基础上加用荷芪散加味治疗。比较两组的治疗效果。结果 治疗3个月后，研究组的血尿酸（UA）、血肌酐（Scr）、空腹胰岛素（FINS）水平及胰岛素抵抗指数（HOMA-IR）低于对照组，胰岛素分泌指数（HOMA-β）、胰岛素敏感指数（HOMA-ISI）高于对照组（P<0.05）。治疗3个月后，研究组的可溶性细胞间黏附因子-1(sICAM-1)、晚期氧化蛋白产物（AOPP）、髓过氧化物酶（MPO）、丙二醛（MDA）及内皮素-1(ET-1)水平低于对照组，一氧化氮（NO）水平高于对照组（P<0.05）。研究组不良反应总发生率为5.00%，显著低于对照组的20.00%，差异具有统计学意义（P<0.05）。结论 荷芪散加味结合非布司他治疗高尿酸血症伴胰岛素抵抗的效果较好，具有较高的临床推广价值。更多还原

【Abstract】 Objective To explore the clinical effect of modified Heqi powder combined with febuxostat in the treatment of hyperuricemia with insulin resistance. Methods A total of 80 patients with hyperuricemia and insulin resistance admitted from January 2020 to January 2021 were selected as the research objects and divided into control group and observation group according to the random number table method, with 40cases in each group. The control group was treated with febuxostat tablets, and the observation group was treated with modified Heqi powder on the basis of the control group. The therapeutic effects of the two groups were compared. Results After 3 months of treatment, the blood uric acid(UA), serum creatinine(Scr), fasting insulin(FINS) levels and homeostasis model assessment of insulin resistance index(HOMA-IR) in the observation group were lower than those in the control group, and the thomeostasis model assessment insulin secretion index(HOMA-β) and homeostasis model assessment-insulin sensitivity index(HOMA-ISI) were higher than those in the control group(P<0.05). After 3 months of treatment, the levels of soluble intercellular adhesion molecule-1(sICAM-1), advanced oxidation protein products(AOPP), myeloperoxidase(MPO), malondialdehyde(MDA) and endothelin-1(ET-1) in the observation group were lower than those in the control group, the level of nitric oxide(NO) was higher than that in the control group(P <0.05). The total incidence of adverse reactions in the observation group was 5.00%, which was significantly lower than 20.00% in the control group,and the difference was statistically significant(P <0.05). Conclusion Modified Heqi powder combined with febuxostat in the treatment of hyperuricemia with insulin resistance has a better effect, with high clinical promotion value.更多还原